Neoadjuvant and Adjuvant Immunotherapy in Resectable NSCLC

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Surgery

Background:

• Early-stage non-small cell lung cancer (NSCLC) presents challenges with poor survival and recurrence rates despite advancements.
• The integration of immune-based therapies, mirroring strategies for advanced NSCLC, is transforming early-stage management.
• Immune-checkpoint inhibitors (ICIs) are being explored in neoadjuvant, adjuvant, and perioperative settings for resectable NSCLC.

Purpose of the Study:

• To review current immunotherapy treatment options for early-stage NSCLC.
• To analyze the advantages and disadvantages of various ICI regimens.
• To discuss persistent challenges and future directions in immunotherapy for resectable NSCLC.

Main Methods:

• Comprehensive literature review of clinical trials and research on ICI in early-stage NSCLC.
• Analysis of treatment strategies including monotherapy, combination therapy, and perioperative approaches.
• Evaluation of biomarker research for predicting treatment response.

Main Results:

• ICI regimens show promise in neoadjuvant, adjuvant, and perioperative settings for early NSCLC.
• Ongoing research aims to personalize ICI treatments for specific patient subsets.
• Biomarker identification is crucial for predicting response and improving survival rates.

Conclusions:

• Immunotherapy, particularly ICIs, represents a significant advancement in the management of resectable NSCLC.
• Optimizing treatment strategies and identifying predictive biomarkers are key to maximizing patient benefit.
• Future research holds the potential to further refine immunotherapy approaches, ushering in a new era for early lung cancer care.